Status:
RECRUITING
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa
Lead Sponsor:
Incyte Corporation
Conditions:
Hidradenitis Suppurativa (HS)
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
The purpose of this study is to evaluate long-term safety and efficacy of povorcitinib in participants with moderate to severe hidradenitis suppurativa who completed the 54 weeks of study treatment wi...
Eligibility Criteria
Inclusion
- Completion of the study treatment period of the originating parent study (INCB 54707-301 or INCB 54707-302).
- Agreement to use contraception.
- Willing and able to comply with the study protocol and procedures.
- Further inclusion criteria apply.
Exclusion
- Participation in the extension study could expose the participant to an undue safety risk.
- Women who are pregnant (or who are considering pregnancy) or breastfeeding.
- Further exclusion criteria apply.
Key Trial Info
Start Date :
January 30 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 26 2026
Estimated Enrollment :
960 Patients enrolled
Trial Details
Trial ID
NCT06212999
Start Date
January 30 2024
End Date
December 26 2026
Last Update
November 4 2025
Active Locations (171)
Enter a location and click search to find clinical trials sorted by distance.
1
Investigative Site US303
Phoenix, Arizona, United States, 85006
2
Investigative Site US240
Scottsdale, Arizona, United States, 85255
3
Investigative Site US307
Fort Smith, Arkansas, United States, 72916
4
Investigative Site US214
Rogers, Arkansas, United States, 72758